Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study - Poll - MDSpire

Infection Risk Assessment of Ocrelizumab Versus Rituximab in Multiple Sclerosis: Findings from a Nationwide Cohort Study in Sweden

  • By

  • Thomas Frisell

  • Sebastian Hedberg

  • Fredrik Piehl

  • June 17, 2026

Share

Original Source(s)

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

  • by Thomas Frisell, Sebastian Hedberg, Fredrik Piehl

  • June 17, 2026

Related Content

Association between peripheral blood T cell subsets and clinical disability in multiple sclerosis patients

A combined therapeutic approach: extracorporeal shock wave therapy and botulinum toxin in multiple sclerosis-related spasticity

Case Report: Multiple sclerosis and Neurofibromatosis type 1: a rare comorbidity